Skip to main content

Advertisement

SpringerLink
Log in

Risikoadaptierte Therapie der akuten myeloischen Leukämie

Risk-adapted therapy of acute myeloid leukemia

  • Individualisierte Therapie – ein Paradigmenwechsel?
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Dank genetischer und molekularer Techniken wurden zunehmende Einblicke in die Biologie der akuten myeloischen Leukämie (AML) gewonnen. Neuere Erkenntnisse zeigen, dass es sich bei der AML nicht um eine homogene Krankheitsentität, sondern um eine heterogene Gruppe biologisch unterschiedlicher Subtypen handelt. Diese Untergruppen werden derzeit überwiegend über zytogenetische und molekulare Marker definiert. Klinisch weisen sie ausgeprägte Unterschiede im Ansprechen auf Therapie und Langzeitergebnisse auf und erlauben daher die Definition von Risikogruppen. Solche Risikogruppen werden in Zukunft Grundlage therapeutischer Entscheidungen sein und letztlich zu einer individualisierten Therapiestrategie führen.

Abstract

Genetic and molecular techniques have provided increasing insights into the biology of acute myeloid leukemia (AML). These investigations showed that AML is not a homogeneous disease but a heterogeneous group of biologically different subentities. These subentities are currently primarily defined by cytogenetics and molecular markers. They differ substantially in response to therapy and long-term outcome and hence allow different risk groups of patients to be defined. These will guide therapeutic decisions in future therapeutic strategies and may ultimately lead to an individualized treatment concept.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Amadori S, Suciu S, Willemze R et al. (2004) Sequential administration of gemtuzumab ozogamacin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 89: 950–956

    PubMed  Google Scholar 

  2. Belhabri A, Thomas X, Wattel E et al. (2002) All trans retinal acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized study. Hematol J 3: 49–55

    Article  PubMed  Google Scholar 

  3. Büchner T, Hiddemann W, Wörmann B et al. (1999) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 93: 4116–4124

    PubMed  Google Scholar 

  4. Byrd JC, Mrozek K, Dodge RK et al. (2002) Cancer and Leukemia Group B (CALGB 8461) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100: 4325–4336

    Article  PubMed  Google Scholar 

  5. Cassinat B, Chomienne C (2001) Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management. Oncogene 20: 7154–7160

    Article  PubMed  Google Scholar 

  6. Estey EH, Thall PF, Pierce S et al. (1999) Randomized phase III study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93: 2478–2484

    PubMed  Google Scholar 

  7. Fröhling S, Schlenk RF, Stolze I et al. (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22: 624–633

    Article  PubMed  Google Scholar 

  8. Greenberg P, Lee S, Advani J et al. (2004) Randomized trial comparing mitoxantrone, etoposide and cytarabine with or without PSC-833 (Valspodar) in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: Eastern Cooperative Oncology Group protocol E 2995. J Clin Oncol 22: 1078–1086

    Article  PubMed  Google Scholar 

  9. Grimwade D, Walker H, Harrison G et al. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98: 1312–1320

    Article  PubMed  Google Scholar 

  10. Haferlach T, Schoch C, Löffler H et al. (2003) Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studie. J Clin Oncol 21: 256–265

    Article  PubMed  Google Scholar 

  11. Harris NL, Jaffe ES, Diebold J et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissue. J Clin Oncol 17: 3835–3849

    PubMed  Google Scholar 

  12. John AM, Thomas NS, Mufti GJ et al. (2004) Semin Cancer Biol 14: 41–62

    Article  PubMed  Google Scholar 

  13. Karp J, Lancet J, Kaufmann S et al. (2001) Clinical and biologic activity of the farnesyltransferase inhibitor R 115777 in adults with refractory and relapsed acute leukemias: a phase I clinical laboratory correlative trial. Blood 97: 3361–3369

    Article  PubMed  Google Scholar 

  14. Lancet JE, Rosenblatt JD, Karp JE (2002) Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of zarnestra activity in high-risk leukemias. Semin Hematol 39 [Suppl 2]: 31–35

    Article  PubMed  Google Scholar 

  15. Larson RA, Boogaerts M, Estey E et al. (2002) Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using mylotarg. Leukemia 16: 1627–1636

    Article  PubMed  Google Scholar 

  16. Lengfelder E, Reichert A, Schoch C et al. (2000) Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 14: 1362–1370

    Article  PubMed  Google Scholar 

  17. List A, Kopecky K, William C et al. (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 98: 3212–3230

    Article  PubMed  Google Scholar 

  18. Look AT (1997) Oncogenic transcription factors in the human acute leukemias. Science 278: 1059–1064

    Article  PubMed  Google Scholar 

  19. Lui Y, Wheatley K, Rees J et al. (2001) Comparison of ‚sequential‚ versus ‚standard‚ chemotherapy as re-induction treatment, with or without cyclosporine in refractory/relapsed acute myeloid leukemia (AML): Results of the UK Medical Research council AML-R trial. Br J Haematol 113: 713–726

    Article  PubMed  Google Scholar 

  20. Marcucci G, Byrd J, Dai G et al. (2003) Phase I and pharmacokinetic studies of G 3139, a Bcl-2 antisense oligonucleotide in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101: 425–432

    Article  PubMed  Google Scholar 

  21. Piazza F, Gurrieri C, Pandolfi PP (2001) The theory of APL. Oncogene 20: 7216–7222

    Article  PubMed  Google Scholar 

  22. Preiss BS, Kerndrup GB, Schmidt KG et al. (2003) AML Study Group Region of Southern Denmark. Cytogenetic findings in adult de novo acute myeloid leukaemia. A population-based study of 303/337 patients. Br J Haematol 123: 219–234

    Article  PubMed  Google Scholar 

  23. Rai KR, Holland JF, Glidewell OJ et al. (1981) Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 58: 1203–1212

    PubMed  Google Scholar 

  24. Schlenk RF, Fröhling S, Hartmann F et al. (2004) Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acue myeloid leukemia. Leukemia 18: 1798–1803

    Article  PubMed  Google Scholar 

  25. Schnittger S, Kinkelin U, Schoch C et al. (2000) Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 14: 796–804

    Article  PubMed  Google Scholar 

  26. Schnittger S, Schoch C, Dugas M et al. (2003) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100: 59–66

    Article  Google Scholar 

  27. Schnittger S, Schoch C, Kern W et al. (2005) Nucleophosmin gene mutations as prognostic predictors in acute myelogenous leukemia with a normal karyotype. Blood, accepted

  28. Schoch C, Haferlach T, Haase D et al. (2001) German AML Cooperative Study Group. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 112: 118–126

    Article  PubMed  Google Scholar 

  29. Schoch C, Schnittger S, Kern W et al. (2003) Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1.897 patients with acute myeloid leukemia. Haematologica 88: 351–352

    PubMed  Google Scholar 

  30. Sievers E, Larson R, Stadtmauer E et al. (2001) Efficacy and safety of gemtuzumab ozogamacin in patients with CD 33 – positive acute myeloid leukemia in first relapse. J Clin Oncol 19: 3244–3254

    PubMed  Google Scholar 

  31. Silverman LR, Demakos EP, Peterson BL et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429–2440

    Article  PubMed  Google Scholar 

  32. Stone RM, O’Donnell MR, Sekeres MA (2004) Acute myeloid leukemia, Hematology: Am Soc Hematol Educ Program 2004, pp 98–117

  33. Tallman MS, Andersen JW, Schiffer CA et al. (2002) All-Trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100: 4298–302

    Article  PubMed  Google Scholar 

  34. Tenen DG (2003) Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3: 89–101

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Keine Angaben

Author information

Authors and Affiliations

  1. Medizinische Klinik III, Universität München, Großhadern, Marchioninistraße 15, 81377 , München

    W. Hiddemann, K. Spiekermann, M. Feuring-Buske & C. Buske

  2. Klinische Kooperationsgruppe Pathogenese akuter myeloischer Leukämien, GSF-Forschungszentrum für Umwelt und Gesundheit, München-Neuherberg

    W. Hiddemann, K. Spiekermann, J. Braess, M. Feuring-Buske & C. Buske

  3. Medizinische Klinik A, Universität Münster

    T. Büchner

Authors
  1. W. Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Spiekermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Braess
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Feuring-Buske
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Buske
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Büchner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Hiddemann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hiddemann, W., Spiekermann, K., Braess, J. et al. Risikoadaptierte Therapie der akuten myeloischen Leukämie. Internist 47 (Suppl 1), S33–S39 (2006). https://doi.org/10.1007/s00108-006-1622-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-006-1622-y

Schlüsselwörter

Keywords

Search

Navigation